Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

Stephen H. Petersdorf, Kenneth J. Kopecky, Marilyn Slovak, Cheryl Willman, Thomas Nevill, Joseph Brandwein, Richard A. Larson, Harry P. Erba, Patrick J. Stiff, Robert K. Stuart, Roland B. Walter, Martin S. Tallman, Leif Stenke, Frederick R. Appelbaum

Blood (2013) 121 (24): 4854–4860.

https://doi.org/10.1182/blood-2013-01-466706

Published: 2013

Journal Articles

Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group

Stella M. Davies, Michael J. Borowitz, Gary L. Rosner, Kristin Ritz, Meenakshi Devidas, Naomi Winick, Paul L. Martin, Paul Bowman, James Elliott, Cheryl Willman, Soma Das, Edwin H. Cook, Mary V. Relling

Blood (2008) 111 (6): 2984–2990.

https://doi.org/10.1182/blood-2007-09-114082

Published: 2008

Includes: Supplemental data

Journal Articles

Genome-Wide Profiling Reveals Recurring Molecular Defects in Relapsed Childhood Acute Lymphoblastic Leukemia (ALL): A Children’s Oncology Group Study.

Jun Yang, PhD, Deepa Bhojwani, M.D., Wenjian Yang, Ph.D., Yiping Fan, Ph.D., Meenakshi Devidas, Stephen Hunger, M.D., Cheryl Willman, M.D., Elizabeth Raetz, M.D., Mary V. Relling, Pharm. D., William L. Carroll, M.D.

Blood (2007) 110 (11): 725.

https://doi.org/10.1182/blood.V110.11.725.725

Published: 2007

Journal Articles

Minimal Residual Disease (MRD) and Risk of Relapse in Acute Promyelocytic Leukemia (APL): Insights from the North American Intergroup Phase III Trial C9710.

Wendy Stock, MD, Richard Harvey, MD, Barry Moser, PhD, Dorie Sher, BS, Esther Schachter-Tokarz, BS, Matthew Myers, BS, James Slack, MD, Bayard Powell, MD, Clara D. Bloomfield, MD, Richard A. Larson, MD, Martin S. Tallman, MD, Frederick R. Appelbaum, MD, James Feusner, MD, Cheryl Willman, MD, Robert Gallagher, MD

Blood (2006) 108 (11): 494.

https://doi.org/10.1182/blood.V108.11.494.494

Published: 2006

Journal Articles

Gene Expression Profiling and FLT3 Status Correlate with Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421.

Norman Lacayo, MD, Soheil Meshinchi, MD, Susana Raimondi, PhD, Chitra Saraiya, MS, Maureen O’Brien, MD, Ronald Yu, PhD, Dejan Juric, MD, Myron Chang, PhD, Cheryl Willman, MD, Robert Tibshirani, PhD, Yaddanapudi Ravindranath, MD, Branimir Sikic, MD, Howard Weinstein, MD, Gary Van Houten Dahl, MD

Blood (2005) 106 (11): 2372.

https://doi.org/10.1182/blood.V106.11.2372.2372

Published: 2005

Journal Articles

Phase III Trial of All-Trans Retinoic Acid (ATRA) vs Daunorubicin (D) and Cytosine Arabinoside (A) as Induction Therapy and ATRA vs Observation as Maintenance Therapy for Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL).

John Gregory, MD, Haesook Kim, PhD, Todd Alonzo, MD, Rob Gerbing, PhD, Angela Ogden, MD, William Woods, MD, Howard Weinstein, MD, Lois Shepherd, MD, Charles Schiffer, MD, Frederick Appelbaum, MD, Cheryl Willman, MD, Peter Wiernik, MD, Jacob Rowe, MD, Martin Tallman, MD, James Feusner, MD

Blood (2005) 106 (11): 894.

https://doi.org/10.1182/blood.V106.11.894.894

Published: 2005

Journal Articles

Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34) Defines a Very Poor Risk Leukemia Subgroup with Distinguishing Clinicopathological Features: A United States (US) Cytogenetics Intergroup Study of 62 AML and MDS Cases.

Marilyn L. Slovak, Clara D. Bloomfield, Holly Gundacker, Gordon Dewald, Frederick R. Appelbaum, Richard A. Larson, Martin S. Tallman, Cheryl Willman, Yaddanapudi Ravindranath, Todd A. Alonzo, Andrew Carroll, Betsy Hirsch, Susana Raimondi, Nyla A. Heerema

Blood (2004) 104 (11): 567.

https://doi.org/10.1182/blood.V104.11.567.567

Published: 2004

Journal Articles

Induction of apoptosis in retinoid-refractory acute myelogenous leukemia by a novel AHPN analog

Blood (2003) 102 (10): 3743–3752.

https://doi.org/10.1182/blood-2003-01-0108

Published: 2003

Journal Articles

All- trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol: Presented in part at the 39th meeting of the American Society of Hematology, New Orleans, LA, December 1999.

Martin S. Tallman, Janet W. Andersen, Charles A. Schiffer, Frederick R. Appelbaum, James H. Feusner, William G. Woods, Angela Ogden, Howard Weinstein, Lois Shepherd, Cheryl Willman, Clara D. Bloomfield, Jacob M. Rowe, Peter H. Wiernik

Blood (2002) 100 (13): 4298–4302.

https://doi.org/10.1182/blood-2002-02-0632

Published: 2002

NARROW

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group

Genome-Wide Profiling Reveals Recurring Molecular Defects in Relapsed Childhood Acute Lymphoblastic Leukemia (ALL): A Children’s Oncology Group Study.

Minimal Residual Disease (MRD) and Risk of Relapse in Acute Promyelocytic Leukemia (APL): Insights from the North American Intergroup Phase III Trial C9710.

Gene Expression Profiling and FLT3 Status Correlate with Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421.

Phase III Trial of All-Trans Retinoic Acid (ATRA) vs Daunorubicin (D) and Cytosine Arabinoside (A) as Induction Therapy and ATRA vs Observation as Maintenance Therapy for Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL).

Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34) Defines a Very Poor Risk Leukemia Subgroup with Distinguishing Clinicopathological Features: A United States (US) Cytogenetics Intergroup Study of 62 AML and MDS Cases.

Induction of apoptosis in retinoid-refractory acute myelogenous leukemia by a novel AHPN analog

All- trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol: Presented in part at the 39th meeting of the American Society of Hematology, New Orleans, LA, December 1999.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only